Bucindolol: New hopes from reviewing past data

Drugs of Today

Volumn 47, Issue 5, 2011, Pages 347-351

  Fiuzat, Mona ^a   O'Connor, C M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUCINDOLOL;

BRADYCARDIA; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INTERMITTENT CLAUDICATION; NONHUMAN; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PROPANOLAMINES;

EID: 80052767045     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.5.1579112     Document Type: Review

References (31)

1. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169): 2001-7.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353(9146): 9-13.
3. Packer, M., Fowler, M.B., Roecker, E.B. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106(17): 2194-9.
4. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334(21): 1349-55.
5. Hunt, S.A., Abraham, W.T., Chin, M.H. et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14): e391-479.
6. Metra, M., Bristow, M.R. Beta-Blocker therapy in chronic heart failure. In: Heart Failure: A Companion to Braunwald's Heart Disease. 2nd Ed. D.L. Mann (Ed.). Elsevier 2010.
7. Scatena, R. Bucindolol (Bristol-Myers Squibb Co). IDrugs 1999, 2(2): 168-83.
8. Incara and Indevus outlicense bucindolol interest for development [news release]. November 21, 2003. http://article.wn.com/view/2003/11/21/Incara-and- Indevus-Outlicense-Bucindolol-Interest-for-Develo/. Accessed November 20, 2010.
9. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol 1995, 75(17): 1220-3.
10. Torp-Pedersen, C., Kober, L., Ball, S. et al. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). Eur J Heart Fail 2002, 4(4): 495-9.
11. ARCA biopharma Company Profile. http://www.arcabiopharma.com/9/ Company%20Profile/. Accessed May 4, 2011.
12. Liggett, S.B., Mialet-Perez, J., Thaneemit-Chen, S. et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103(30): 11288-93.
13. Bristow, M.R., Murphy, G.A., Krause-Steinrauf, H. et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine- lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010, 3(1): 21-8.
14. Hershberger, R.E., Wynn, J.R., Sundberg, L., Bristow, M.R. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990, 15(6): 959-67.
15. Bristow, M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101(5): 558-69.
16. Nelson, B., Morrison, J., Nelson, P., Port, J.D., Robertson, A.D., Bristow, M.R. Beta-blocking agents have codon 389 Arg/Gly genotype specific effects in isolated human heart preparations. J Am Coll Cardiol [56th Annu Sci Sess Am Coll Cardiol (ACC) (March 24-27, New Orleans) 2007] 2007, 49(9, Suppl. A): Abst 1022-100.
17. Mason, D.A., Moore, J.D., Green, S.A., Liggett, S.B. A gain-of- function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274(18): 12670-4.
18. Walsh, R., Farmer, R., Kelly, M., Nelson, P., Morrison, J., Port, J.D., Bristow, M.R. Human myocardial beta1 389 Arg/Arg adrenergic receptors exhibit a propensity for constitutively active, high affinity agonist binding and are selectively inactivated by bucindolol. J Cardiac Fail [12th Annu Sci Meet Heart Fail Soc Am (HFSA) (Sept 21-24, Toronto) 2008] 2008, 14(6, Suppl.): Abst 020.
19. Bristow, M.R., Roden, R.L., Lowes, B.D., Gilbert, E.M., Eichhorn, E.J. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 1998, 21(12, Suppl. 1): I3-13.
20. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344(22): 1659-67.
21. Conner, D.P., Vlasses, P.H., Clementi, R.A., Oren, A., Deitchman, D., Ferguson, R.K. Hemodynamic effects during rest and exercise of bucindolol in hypertensive men. J Clin Pharmacol 1987, 27(4): 300-3.
22. Kimura, S., DeQuattro, V., Edmiston, W.A. et al. Efficacy of bucindolol in systemic hypertension. Am J Cardiol 1987, 60(13): 1083-6.
23. Bett, N., Dryburgh, L., Boyle, C., Hawley, C. Hemodynamic properties of bucindolol, a beta-adrenoreceptor blocking drug with vasodilator activity. Am J Cardiol 1986, 57(8): 678-81.
24. Rosendorff, C., Goodman, C., Coull, A. Short- and long-term studies of bucindolol in mild to moderate hypertension: efficacy, safety, and exercise responses. J Clin Pharmacol 1985, 25(3): 233-6.
25. Gilbert, E.M., Anderson, J.L., Deitchman, D. et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990, 88(3): 223-9.
26. Eichhorn, E.J., McGhie, A.L., Bedotto, J.B. et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991, 67(1): 67-73.
27. Woodley, S.L., Gilbert, E.M., Anderson, J.L. et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991, 84(6): 2426-41.
28. Lindenfeld, J., Plehn, J., Liggett, S. et al. Different patterns of LVEF/remodeling and clinical endpoint effects of bucindolol in beta-1 389 Arg/Gly genotypes. J Cardiac Fail [12th Annu Sci Meet Heart Fail Soc Am (HFSA) (Sept 21-24, Toronto) 2008] 2008, 14(6, Suppl.): Abst 127.
29. Tate, C.W., 3rd, Robertson, A.D., Zolty, R. et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail 2007, 13(9): 732-7.
30. O'Connor, C.M., Gottlieb, S., Bourque, J.M. et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. Am J Cardiol 2005, 95(5): 558-64.
31. Bristow, M.R., Eichhorn, E., Ventura, H., Koch, B., Fiuzat, M., Davis, G., Robertson, A.D. Beta-blocker Evaluation of Survival Trial (BEST) findings show benefit of bucindolol in moderate to severe HF patients, according to pre-specified statistical analysis plan. J Am Coll Cardiol [58th Annu Sci Sess Am Coll Cardiol (ACC) (March 29-31, Orlando) 2009] 2009, 53(10, Suppl. A): Abst 1024-184.